1. Lopez AD, Murray CCJL 1998 The global burden of disease, 1990-2020. Nature Medicine 4:1241-1243
2. Lerner DJ, Kannel WB 1986 Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am J Cardiol 111:383-390
3. Lloyd-Jones DM, Larson MG, Beiser A, Levit D 1999 Lifetime risk of developing coronary heart disease, Lancet 353:89-92
4. Kalin MF, Zumoff B 1990 Sex hormones and coronary disease: a review of the clinical studies. Steroids 55:330-352
5. Hayward CS, Kelly RP, Collins P 2000 The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res. 46: 28-49
6. Bhasin S, Bremner WJ 1997 Clinical review 85: emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 82:3-7
7. Davies SR 1999 Androgens replacement in women: a commentary. J Clin Endocrinol Metab 84:1886-1891
8. Mendoza SG, Zerpa A, Carrasco H, Colmenares G, Rangel A, Gartside PS, Kashyap ML 1983 Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol and lipolytic enzymes in men with premature myocardial infarction and andiographically assessed coronary occlusion. Artery 12:1-23
9. Barth JD, Jansen H, Hugenholtz PG, Birkenhager JC 1983 Post heparin lipases, lipids and related hormones in men undergoing coronary arteriography to assess atherosclerosis. Atherosclerosis 48:235-241
10. Hromadova M, Hacik T, Riecansky I 1985 Concentration of lipid, apoprotein-B and testosterone in patients with coronarographic findings. Klin Wochenschr 63:1071-1074
11. Breier C, Muhlberger V, Drexel H, Herold M, Lisch HJ, Knapp E, Braunsteiner H 1985 Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease. Lancet 1:1242-1244
12. Aksut SV, Aksut G, Karamehmetoglu A, Oram E 1986 The determination of serum estradiol, testosterone and progesterone in acute myocardial infarction. Jpn Heart J 27: 825-837
13. Sewdarsen M, Jialal I, Vythilingum S, Desai R 1986 Sex hormone levels in young Indian patients with myocardial infarction. Arteriosclerosis 6: 418-421
14. Chute CG, Baron JA, Plymate SR, Kiel DP, Pavia AT, Lozner EC, O'Keefe T, MacDonald GJ 1987 Sex hormones and coronary artery disease. Am J Med 83:853-859
15. Hämäläinen E, Tikkanen H, Härkonen M, Näveri H, Adlercreutz H 1987 Serum lipoproteins, sex hormones and sex hormone binding globulin in middle-aged men of different physical fitness and risk of coronary heart disease. Atherosclerosis 67:155-162
16. Lichtenstein MJ, Yamell JW, Elwood PC, Beswick AD, Sweetnam PM, Marks V, Teale D, Riad-Fahmy D 1987 Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol 126:647-657
17. Swartz CM, Young MA 1987 Low serum testosterone and myocardial infarction in geriatric male inpatients. J Am Geriatr Soc 35:39-44
18. Sewdarsen M, Jialal I, Naidu RK 1988 The low plasma testosterone levels of young Indian infarct survivors are not due to a primary testicular defect. Postgrad Med J 64:264-266
19. Sewdarsen M, Vythilingum S, Jialal I, Desai RK, Becker P 1990 Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men. Atherosclerosis 83:111-117
20. Rice T, Sprecher DL, Borecki IB, Mitchell LE, Laskarzewski PM, Rao DC 1993 Cincinnati Myocardial Infarction and Hormone Family Study: family resemblance for testosterone in random and MI families. Am J Med Gen 47:542-549
21. Phillips GB, Pinkernell BH, Jing TY 1994 The association of hypotestosteronemia with coronary artery disease in men. Arteriscler Thromb 14:701-706
22. Zhao SP, Li XP 1998 The association of low plasma testosterone level with coronary artery disease in Chinese men. I J Cardiol 63:161-164
23. English KM, Mandour O, Steeds RP, Jones TH, Channer KS 2000 Men with coronary disease have lower levels of androgens than those with coromnary angiograms. Europ Heart J 21:890-895
24. Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A, Pols, HAP 2002 Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87:3632-3639
25. Luria MH, Johnson MW, Pego R, Seuc CA, Manubens SJ, Wieland MR, Wieland RG 1982 Relationship between sex hormones, myocardial infarction, and occlusive coronary disease. Arch Intern Med 142:42-44
26. Labropoulos B, Velonakis E, Oekonomakos P, Laskaris J, Katsimades D 1982 Serum sex hormones in patients with coronary disease and their relationship to known factors causing atherosclerosis. Cardiology 69:98-103
27. Zumoff B, Troxler RG, O'Connor J, Rosenfeld RS, Kream J, LEvin J, Hickman JR, Sloan AM, Walker W, Cook RL, Fukushima DK 1982 Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis 2:58-67
28. Phillips GB, Castelli WP, Abbott RD, McNamara PM 1983 Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med 74:863-869
29. Heller RF, Wheeler MJ, Micallef J, Miller NE, Lewis B 1983 Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin. Acta Endocrinologica 104:253-256
30. Small M, Lowe GDO, Beastall GH, Beattie JM, McEachern M, Hutton I, Lorimar AR, Forbes CD 1985 Serum oestradiol and ischaemic heart diesase relationship with myocardial infarction but not coronary atheroma or haemostasis. Q J Med 57:775-782
31. Franzen J, Fex G 1986 Low serum apolipoprotein A-1 in acute myocardial infarction survivors with normal HDL cholesterol. Atherosclerosis 59:37-42
32. Baumann G, Reza P, Chatterton R, Green D, Krumlovsky F 1988 Plasma estrogens, androgens, and von Willebrand factor in men on chronic hemodialysis. Int J Artif Organs 11:449-453
33. Slowinska-Srzednicka J, Zgliczynski S, Ciswicka-Sznajderman M, Scredicki M, Soszynski P, Biernacka M, Woroszylska M, Ruzyllo W, Sadowski Z 1989 Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 79:197-203
34. Cengiz K, Alvur M, Dindar U 1991 Serum creatinine phophokinase, lactic dehydrogenase, estradiol, progesterone, and testosterone levels in male patients with acute myocardial infarction and unstable angina pectoris. Mater Med Pol 23:195-198
35. Hauner H, Stangl K, Burger K, Busch U, Blomer H, Pfeiffer EF 1991 Sex hormone concentration in men with angiographically assessed coronary artery disease - relationship to obesity and body fat distribution. Klin Wochenschr 69:664-668
36. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM 1994 Evidence for an association between dehydroepiandrosterone sulfate and non-fatal, premature myocardial infarction in males. Circulation 89: 89-93
37. Marquez-Vidal P, Sie P, Cambou J-P, Chap H, Perret B 1995 Relationships of plasminogen activator inhibitor activity and lipoprotein (a) with insulin, testosterone, 17(-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab 80:1794-1798
38. Feldman HA, Johannes CB, McKinlay JB, Longcope C 1998 Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. Ann Epidemiol 8:217-228
39. Kabakci G, Yildirir A, Can I, Unsal I, Erbas B 1999 Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology 92:221-225
40. Schuler-Lüttmann, S, Mönnig, G, Enbergs, A, Schulte, H, Breithardt, G, Assmann, G, Kerber, S, von Eckardstein, A 2000 Insulin-like growth factor binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler. Thromb. Vasc. Biol.. 20: e10-e15
41. Cauley JA, Gutai JP, Kuller LH, Dai WS 1987 Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 60:771-777
42. Barrett-Connor E, Khaw KT 1988 Endogenous sex hormones and cardiovascular disease in men. A prospective population based study. Circulation 78:539-545
43. Phillips GB, Yano K, Stemmerman GN 1988 Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol 41:1151-1156
44. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM 1990 Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 11:460-70
45. Yarnell JWG, Beswick AD, Sweetnam PM, Riad-Fahmy D 1993 Endogenous sex hormones and ischaemic heart disease in men. The Caerphilly Prospective Study. Arteriosclerosis and Thrombosis 13:467-471
46. Hautenen A, Manttari M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H 1994 Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 105:191-200
47. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86:724-731
48. Barrett-Connor EL, Goodman-Gruen D 1995 Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Br Med J 311:1193-1196
49. Phillips GB, Pinkernell BH, Jing TY 1997 Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol Apr;17(4):695-701
50. Bernini GP, Sgro' M, Moretti A, Argenio GF, Barlascini CO, Cristofani R, Salvetti A 1999 Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 84:2008-2012
51. Dahlgren E, Johannson S , Lindstedt G , Knutsson F , Oden A , Janson PO , Mattson L A , Crona N and Lundberg PA 1992a Woman with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focussing on natural history and circulating hormones Fertil Steril , 57, 505-513
52. Wild RA, Grubb B, Hartz van Nort JJ, Bachman W, Bartholomew M 1990 Clinical signs of androgen excess as rsik factors fro coronary artery disease. Fertil Steril 54:255-259
53. Birdsall M, Farquhar C, White H 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126: 32-35
54. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174:1224-9; discussion 1229-1232
55. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414-21
56. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J 2000 Increased risk of non-insulin dependent diabetes mullitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovarian syndrome Human Reprod 15: 785-789.
57. Christian RC, Dumesic DA, Yrtiska HJ et al 2000 Clinical hyperandrogenism and body mass indexpredict coronary calcification in perimenopausal women with polcystic ovarian syndrome. Presented at the Endocrine Society Annual Meeting, Toronto, Canada, June 21-24
58. Mather KJ, Kwan F, Corenblum B 2000 Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 73:150-156
59. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581-586
60. Wild S, Pierpoint T, McKeigue P, Jacobs HS 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.. Clin Endocrinol (Oxf) 52:595-600
61. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes, hypertension, and cardiac complaints in a follow-up study of a Dutch PCOS population. Human Reprod 16:556-560
62. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE 2002 Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87:2013-2017 2002
63. Hamilton & Mestler 1969 Mortality and survival: comparison of eunuchs with intact men and women in a mentally retarded population. J Gerontol 24:395-411
64. Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ 1997 Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 47:337-342
65. Wilson JD 1988 Androgen abuse by athletes. Endocr Rev 9:181-199
66. Council on Scientific Affairs 1990 Medical and Non-medical uses of anabolic-androgenic steroids. JAMA 264:2923-2937
67. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS 1993 Anabolic-androgen steroid use in the United States. JAMA 270:1217-1221.
68. Yesalis, C. E. and M. S. Bahrke (2000). Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab 14(1): 25-35
69. Nilsson, S., A. Baigi, et al. (2001). The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health 11: 195-7
70. Rockhold RW 1993 Cardiovascular toxicity of anabolic steroids. Ann Rev Pharmacol Toxicol 33:497-520
71. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ 1998 The cardiac toxicity of anabolic steroids. Prog Cardiovas Dis 41:1-15
72. Parssinen, M. Kujala, U. Vartiainen, E. Sarna, S. Seppala, T. (2000). Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 21: 225-7
73. Fineschi, V., Baroldi, G., Monciotti, F., Paglicci Reattelli, L., Turillazzi, E. (2001). Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 125: 253-5
74. Webb CM, Adamson DL, de Zeigler D, Collins P 1999 Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83:437-439.
75. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P 1999b Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690-1696
76. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL 1999 Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 99: 1666-1670
77. Jaffe MD 1977 Effect of testosterone on on postexercise ST segment depression. Br Heart J 39: 1217-1222
78. Wu SZ, Weng XZ 1993 Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J 106:415-418
79. English KM, Steed RP, Diver MJ, Jones TH, Channer KS 2000 Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation 102:1906-1911
80. Snyder PJ 2001 Editorial: the role of androgens in women. J Clin Endocrinol Metab 86:1006-1007
81. Miller KK, Sesmilo G, Schiller A, Schonfeld D, Burton S, Klibanski A 2001 androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 86:561-567
82. Lobo RA 2001 Androgens in postmenopausal women: Production, possible role, and replacement options. Obstet Gynecol Survey 56:361-376
83. Bachmann G, Bancroft, J, Braunstein, G, Burger, H, Davis, S, Dennerstein L, et al 2002 Female androgen insufficiency: the princeton consensus statement on definition, classification, and assessment. Fertil Steril, 77:660-665
84. Braunstein, GD 2002 Androgen insufficiency in women: summary of critical issues. Fertil Steril 77 Suppl 4:94-99
85. Padero MCM, Bhasin S, Friedman TC 2002 Androgen supplementation in older women: too much hype, not enough data. J Am Geriatr Soc 50:1131-1140
86. Vermeulen A 1995 Dehydroepiandrosterone sulfate and ageing. Ann NY Acad Sci 774:121-127
87. Birkenhager-Gillesse EG, Derksen J, Lagaay AM 1994 Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. Ann N Y Acad Sci 719:543-552
88. Nafziger AN, Herrington DM, Bush TL 1991 Dehydroepiandrosterone and Dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev 13:267-293
89. Ebeling P, Koivisto VA 1994 Physiological importance of dehydroepiandrosterone. Lancet 343:1479-1481
90. Khaw KT 1996 Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J Endocrinol, 150 Suppl:S149-S153
91. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez JL, Candas B 1998 DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63:322-328
92. Barrett-Connor E, Khaw KT, Yen SSC 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519-1524
93. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA 1990 Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 16:862-870
94. LaCroix AZ, Yano K, Reed DM 1992 Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 86:1529-1535
95. Ishihara F, Hiramatsu K, Shigematsu S, Aizawa T, Niwa A, Takasu N, Yamada T, Matsuo K 1992 Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology 80:332-338
96. Herrington DM 1995 Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci 774:271-280
97. Barrett-Connor E, Goodman-Gruen D 1995 The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci Dec 774:259-270
98. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ 1994 Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol 140:870-875
99. Berr C, Lafon S, Debuire B, Dartigues J-F, Baulieu E-E 1996 Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological and mental status and short-term mortality: a French community-based study. Proc Natl Acad Sci USA 93:13410-13415
100. Jansson JH, Nilsson TK, Johnson O 1998 von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80:334-337
101. Tilvis RS, Kahonen M, Harkonen M 1999 Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano) 11:30-34.
102. Kiechl S, Willeit J, Bonora E, Schwarz S, Xu Q 2000 No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). Arterioscler Thromb Vasc Biol 20:1094-1100
103. Trevedi DP, Khaw KT 2001 Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 86:4171-4177.
104. Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K, Tsunoda R, Kawano H, Kugiyama K, Ogawa H, Saito Y, Nakao K 2000 The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 85:1834-1840
105. Slowinska-Srzednicka J, Malczewska B, Srzednicki M, Chotkowska E, Brzezinska A, Zgliczynski W, Ossowski M, Jeske W, Zgliczynski S, Sadowski Z 1995 Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J Intern Med 237:465-472
106. Barrett-Connor EL, Khaw KT 1987 Absence of an inverse relation of dehydroepiandrosteroneysulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 317:711
107. Barrett-Connor EL, Goodman-Gruen D 1995 Dehydrepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. Circulation 15: 1757-1760
108. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K 1993 Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99:79-86
109. Bruch B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, Benda N, Schmahl FW, Haasis R, Hanke H 1997 Gender-specific differences in the effects of testosterone and estrogen on thedevelopment of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17:2192-2199
110. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C 1999 Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 84:813-819
111. Toda T, Toda Y, Cho BH, Kummerow FA 1984 Ultrastructural changes in the comb and aorta of chicks fed excess testosterone. Atherosclerosis 51: 47-53
112. Adams MR, Williams JK, Kaplan JR 1995 Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15:562-570
113. Elhage R, Arnal JF, Pieraggi M-T, Duverger N, Fiévet C, Faye JC, Bayard F 1997 17?-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc Biol 17: 2679-2684
114. von Dehn G, von Dehn O, Völker W, Langer C, Weinbauer GF, Behre HM, Nieschlag E, Assmann G, von Eckardstein A 2001 Atherosclerosis in apolipoprotein E-deficient mice is increased by exogenous androgens and decreased by suppression of endogenous testosterone. Horm Metab Res in press.
115. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G. Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase. Proc Natl Acad Sci U S A. 2001 98:3589-3593.
116. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN 1989 Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbits. Arteriosclerosis 9:159-165
117. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML 1993 Inhibition of accelerated coronary atherosclerosis with dehydroepinadrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261-265
118. Hayashi T, Esaki T, Muto E, Kano H, Asai Y, Thakur NK, Sumi D, Jayachandran M, Iguchi A 2000 Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 20:782-92.
119. Barret-Connor EL 1995 Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab 21: 156-161
120. Kiel DP, Baron CA, Plymate SR 1989 Sex hormones and lipoproteins in men. Am J Med 87: 35-39
121. Hergenc, G, Schulte, H, Assmann, G, von Eckardstein, A 1999 Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 145: 147-156
122. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E 1997 Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 82:682-685
123. Hautanen A 2000 Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord. 24 Suppl 2:S64-70
124. Björntorp P 1996 The regulation of adipose tissue distribution in humans Int J Obesity 20: 291-302
125. Leenen R, van der Kooy K, Seidell JC, Deurenberg P, Koppeschaar HP 1994 Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy J Clin Endocrinol Metab 78: 1515-1520
126. Pasquali R, Macor C, Vicennati V, Novo F, De lasio R, Mesini P, Boschi S, Casimirri F, Vettor R 1997 Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism. 46:526-9.
127. Couillard C, Gagnon J, Bergnon J, et al 2000 Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroids hormone concentration in men: the HERITAGE family study. J Clin Endocrinol Metab 85:1026-1031.
128. Behre HM, Simoni M, Nieschlag E 1997 Strong association between serum levels of leptin and testosterone in men. Clin Endocrinol 47: 237-240
129. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab. 85:2839-2853.
130. Büchter, D, Behre, HM, Kliesch, S, Chirazi, A, Nieschlag, E, Assmann, G, von Eckardstein, A 1999a Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Experiment. Clin. Endocrinol. Diabet. 107, 522-529
131. Zitzmann, M, Gromoll, J, von Eckardstein, A, Nieschlag, E 2003 The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum levels of leptin and insulin in men Diabetologia, in press
132. Dieudonne MN, Pecquery R, Leneveu MC, Giudicelli Y 2000 Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology 141:649-656.
133. Björntorp P 1994 Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol 5:166-174
134. Lindstedt G, Lundberg P, Lapidus L, Lundgren H, Bengtsson C, Björntorp P 1991 Low sex hormone binding globulin concentration as an independent risk factor for development of NIDDM: 12 yr follow up of population study of women in Gothenburg. Diabetes 40:123-128
135. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800
136. Amowitz LL, Sobel BE 1999 Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28(2):439-58
137. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F 1998 Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83: 2001-2005.
138. Dunaif A, Thomas A 2001 Current concepts in the polycystic ovarian syndrome. Ann Rev Med 52:401-419.
139. Pasquali R, Filicori M 1998 Insulin sensitizing agents and polycystic ovary syndrome. Eur J Endocrinol. 138:253-254.
140. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L 2000 Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73:1149-1154
141. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO 1998 Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13:2706-11
142. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ 1998 The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83:2699-705
143. Lemieux S, Lewis GF, Ben-Chetrit A, Steiner G, Greenblatt EM 1999 Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab 84:4278-4282.
144. Polderman KH, Gooren LJ, Asschermann H et al 1994 Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79:265-271
145. Nilsson C, Niklasson M, Eriksson E, Bjorntorp P, Holmang A 1998 Imprinting of female offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats. J Clin Invest 101:74-78
146. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH 2000 Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 85:1206-10
147. Kirkland RT, Keenan BS, Probstfield JL, Patsch W, Tsai-Lien L, Clayton GW, Insull Jr W 1987 Decrease in plasma high density lipoprotein cholesterol levels at puberty in boys with delayed adolescence: Correlation with plasma testosterone levels JAMA 257: 502-507
148. Wu, FCW & von Eckardstein 2003. Androgens and Coronary Artery Disease. Endocrine Reviews, in press.
149. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS 2001 Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 111:261-269
150. von Eckardstein, A, Nofer, JR, Assmann, G 2001 HDL and coronary heart disease: Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 20: 13-27
151. Langer, C, Gansz, B, Goepfert, C, Engel, T, Uehara, Y, von Dehn, G, Jansen, H, Assmann, G, von Eckardstein, A (2002).Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun 296: 1051-1057
152. Tan KC, Shiu SW, Kung AW 1999 Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clin Endocrinol (Oxf) 51:765-9.
153. Flynn MA, Weaver-Osterholtz D, Sharper-Timms KL, Allen S, Krause G 1999 Dehydroepiandrosterone replacement in aging human. J Clin Endocrinol Metab 84: 1527-1533
154. Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B 2001 Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 86:4686-4692
155. Nippoldt TB, Nair KS 1998 Is there a case for DHEA replacement? Baillière's Clin Endocrinol Metab 12: 507-20
156. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JAH, Herbert J, Chatterjee VKK 2000 Improvement in mood and fatigue after dehydroepiandrosterone replacement in addison's disease in a randomised, double blind trial. J Clin Endocrinol Metab 85:4650-4656.
157. Arlt W, Haas J, Callies F, Reincke M, Hubler D, Oettel M, Ernst M, Schulte HM, Allolio B 1999 Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng J Med 341:1013-1020.
158. Danesh J, Collins R, Peto R. 2000. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 102:1082-5
159. Anderson RA, Wallace EM, Wu FCW 1995 Effects of testosterone enanthate on serum lipoproteins in man. Contraception 52:115-119.
160. Angelin B 1997 Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol 8: 337-341
161. von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM 1997 Suppression of endogenous testosterone in young men increases serum levels of HDL-subclass LpA-I and lipoprotein(a). Clin Endocrinol Metab 82: 3367-3372
162. Ridker, PM 1999 Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann. Intern. Med. 130:933-937
163. Anderson RA, Ludlam CA, Wu FCW 1995b Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 74: 693-697
164. Eri LM, Urdal P, Bechensteen AG 1995b Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 154: 100- 104
165. Winkler UH 1996 Effects of androgens on haemostasis Maturitas 24: 147-155
166. Ross R 1999 Atherosclerosis--an inflammatory disease. N Engl J Med. 340:115-126.
167. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS 1998 Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol. 32:1331-5
168. Herman SM, Robinson JTC, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS 1997 Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 17: 2004-2009
169. Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, Nieschlag E 2001 The CAG repeat polymorphism in the androgen receptor gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J. Clin. Endocrinol. Metab. 86: 4867-4873
170. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, Chatterjee K 1996 Testosterone induces dilatation of canine coronary conductance and resistance arteries in vivo. Circulation 94: 2614-2619
171. Costarella CE, Stallone JN, Rutecki GW, Whittier FC 1996 Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Experiment Therap 277: 34-39
172. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P 1995 Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91: 1154-1160
173. Teoh H, Quan A, Leung SW, Man RY 2000 Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. Br J Pharmacol 129:1301-1308
174. Ceballos G, Figueroa L, Rubio I, Gallo G, Garcia A, Martinez A, Yanez R, Perez J, Morato T, Chamorro G 1999 Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol. 33:691-7
175. Farhat MY, Wolfe R, Vargas R, Foegh ML, Ramwell 1995 Effect of testosterone treatment on vasoconstrictor response of left anterior descend coronary artery in male and female pigs. J Cardiovasc Pharmacol 25: 495-500
176. Hutchison SJ, Sudhir K, Chou TM, Sievers RE, Zu BQ, Sun YP, Deedwania PC, Glntz SA, Parmely WW, Chatterjee K 1997 Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. J Am Coll Cardiol 29: 800-807
177. Geary GG, Krause DN, Duckles SP 2000 Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am J Physiol Heart Circ Physiol. 279:H610-H618
178. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T 1995 Up regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 360: 291-295
179. Masuda A, Mathur A, Halushka PV 1995 Testosterone increases thromboxane A2 receptors in cultured rat smooth muscle cells. Circ Res 69: 638-643
180. Harada, Sasano, Murakami H, Ohkuma T, Nagura H, Takagi Y 1999 Localised expression of aromatse in human vascular tissue. Circ Res 84:1285-1291.
181. McCrohon JA, Death AK, Nakhla S, Jessup W, Handelsman DJ, Stanley KK, Celermajer DS 2000 Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 101:224-226
182. Lieberherr M, Grosse B 1994 Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem. 269:7217-7223
183. Glass CK, Witztum JL 2001 Atherosclerosis. the road ahead. Cell. 104:503-516
184. Zhu XD, Bonet B, Knopp RH 1997 17(-estradiol, progesterone, and testosterone inversely modulate low density lipoprotein oxidation and cytotoxicity in cultured placental trophoblast and macrophages. Am J Obstet Gynecol 177: 196-209
185. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, Eto M, Toba K, Orimo H 1997 Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130: 1-10
186. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R 1996 Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 148: 969-976
187. Grumbach MM, Auchus RJ 1999 Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84:4677-4694
188. Diano S, Horvath TL, Mor G, Register T, Adams M, Harada N, Naftolin F 1999 Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6:21-28
189. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD 2000 Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation 101:1792-1798
190. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab Dec;80(12):3689-98
191. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER 1997 Effect of testosterone and oestradiol in a man with aromatase deficiency. New Eng J Med 337:91-95
192. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-61
193. Sudhir K, Chou TM, Chatterjee K, Smith EP, Williams TC, Kane JP, Malloy MJ, Korach KS, Rubanyi GM 1997a Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96:3774-3777.
194. Sudhir K, Chou TM, Messina LM, Hutchison SJ, Korach KS, Chatterjee K, Rubanyi GM 1997b Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349:1146-1147
195. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly M, Rudling M, Lindberg MK, Warner M, Angelin B, Gustafsson JA 2000 Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun 30;278:640-645
196. Nemoto Y, Toda K, Ono M, Fujikawa-Adachi K, Saibara T, Onishi S, Enzan H, Okada T, Shizuta Y 2000 Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest105:1819-1825
197. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS 2000 Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A 97:12729-12734
198. Rubanyi GM, Frey AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS 1997 Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. J Clin Invest 99:2429-2437.
199. Nilsson BO, Ekblad E, Heine T, Gustafsson J 2000 Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor ? knock-out mice. J Endocrinol166:R5-R9
200. White MM,, Zamudio S, Stevens T, et al 1995 Estrogen, progesterone and vascular reactivity: potential cellular mechanisms. Endocr Rev 16:739-751.
201. Sudhir K, Komesaroff PA 1999 Cardiovascular actions of estrogens in men. J Clin Endocrinol Metab 84:3411-3415.
202. Nathan L, Chaudhuri G 1997 Estrogens and atherosclerosis. Ann Rev Pharamcol Toxicol 37:477-515.
203. Shaul PW 2000 Novel role of estrogen receptors in vascular endothelium. Semin Perinatol 24:70-74
204. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Howalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D 2000 Effects of extrogen replacement on the progression of coronary artery artherosclerosis. N Eng J Med 343:522-529.
205. Hulley S, Grady D, Bush T, Furberg C, Herrington DM, Riggs B, Vittinghoff E 1998 Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: The HERS study. JAMA 280:605-613
206. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288:321-333
207. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H; The ESPRIT team. 2002 Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 28;360:2001-2008